Long-term follow-up data of MonarchE confirm adjuvant abemaciclib plus endocrine therapy as standard of care for patients with high-risk, HR+/HER2- early breast cancer

October 2023 ESMO 2023 Tom Feys

In this episode, Prof. Dr. Patrick Neven will discuss the long-term follow-up data of the MonarchE trial. With a median follow-up of 4.5 years, updated results solidify that adding abemaciclib to endocrine therapy significantly improves the invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in patients with high-risk, HR+/HER2-, node positive early breast cancer, with a further separation of IDFS and DRFS curves.